Published in J Med Chem on July 16, 1998
2-Benz-yloxy-1,2,4-triazolo[1,5-a]quinazolin-5(4H)-one. Acta Crystallogr Sect E Struct Rep Online (2011) 1.73
Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov (1999) 1.21
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile. Purinergic Signal (2006) 0.96
Evidence for an atypical receptor mediating the augmented bronchoconstrictor response to adenosine induced by allergen challenge in actively sensitized Brown Norway rats. Br J Pharmacol (2002) 0.84
Functional selectivity of adenosine A1 receptor ligands? Purinergic Signal (2012) 0.81
The receptor mechanism mediating the contractile response to adenosine on lung parenchymal strips from actively sensitised, allergen-challenged Brown Norway rats. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.81
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol (2005) 0.76
Break Down in Order To Build Up: Decomposing Small Molecules for Fragment-Based Drug Design with eMolFrag. J Chem Inf Model (2017) 0.75
Synthesis and Anticancer Activity of 2-(Alkyl-, Alkaryl-, Aryl-, Hetaryl-)-[1,2,4]triazolo[1,5-c]quinazolines. Sci Pharm (2012) 0.75
Potent P2X7 Receptor Antagonists: Tyrosyl Derivatives Synthesized Using a Sequential Parallel Synthetic Approach. Drug Dev Res (2001) 0.75
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev (1998) 6.74
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry (2001) 4.37
Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry (2001) 4.13
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
Direct observation of brownian motion of lipids in a membrane. Proc Natl Acad Sci U S A (1991) 3.91
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest (2001) 3.86
Diffusion of injected macromolecules within the cytoplasm of living cells. Proc Natl Acad Sci U S A (1981) 3.61
Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci (2001) 3.46
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity (1999) 2.74
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther (2005) 2.71
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev (1999) 2.56
Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J Med Chem (1985) 2.52
Isolation and characterization of new fission yeast cytokinesis mutants. Genetics (1998) 2.51
Structural mosaicism on the submicron scale in the plasma membrane. Biophys J (1998) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
Unconfined lateral diffusion and an estimate of pericellular matrix viscosity revealed by measuring the mobility of gold-tagged lipids. J Cell Biol (1993) 2.47
Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol (1994) 2.33
Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology (2000) 2.26
V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2001) 2.19
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther (2014) 2.17
Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem (2001) 2.14
Spatial Fourier analysis of video photobleaching measurements. Principles and optimization. Biophys J (1991) 2.13
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem (1985) 2.12
Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst (2001) 2.12
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci (1997) 2.09
Prospective comparison treatment of 595-nm pulsed-dye lasers for virgin port-wine stain. Br J Dermatol (2015) 1.96
Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology (1997) 1.94
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem (1995) 1.92
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci U S A (1986) 1.85
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem (2000) 1.85
Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J Med Chem (1993) 1.84
Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br J Pharmacol (1998) 1.80
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther (2012) 1.79
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology (1997) 1.78
Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol (1994) 1.77
Lower diffusion in white matter of children with prenatal methamphetamine exposure. Neurology (2009) 1.76
The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther (2004) 1.76
DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol (2000) 1.68
Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation (1998) 1.65
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem (2000) 1.65
Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry (1999) 1.64
Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med (2001) 1.64
A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol (1997) 1.63
Characterization of newly emerging Newcastle disease virus isolates from the People's Republic of China and Taiwan. J Clin Microbiol (2001) 1.63
A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc Natl Acad Sci U S A (1998) 1.63
Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther (2011) 1.63
Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci (2011) 1.62
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
The role of the sid1p kinase and cdc14p in regulating the onset of cytokinesis in fission yeast. EMBO J (2000) 1.62
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem (1998) 1.61
Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology (2002) 1.61
Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem (1998) 1.61
fMRI-acoustic noise alters brain activation during working memory tasks. Neuroimage (2005) 1.60
Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest (1996) 1.57
A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol (1992) 1.57
Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol (1995) 1.57
Functional GI disorders: from animal models to drug development. Gut (2007) 1.55
A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. Mol Pharmacol (1986) 1.55
Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil (2013) 1.55
Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol (1996) 1.54
The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem (1999) 1.54
Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett (1985) 1.52
Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry (2001) 1.52
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem (1997) 1.51
Direct measurement of lateral transport in membranes by using time-resolved spatial photometry. Proc Natl Acad Sci U S A (1985) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol (1997) 1.49
Identification of conserved, RpoS-dependent stationary-phase genes of Escherichia coli. J Bacteriol (1998) 1.49
Brain areas specific for attentional load in a motion-tracking task. J Cogn Neurosci (2001) 1.48
Molecular probes for extracellular adenosine receptors. Biochem Pharmacol (1987) 1.47
Gender-related differences in IBS symptoms. Am J Gastroenterol (2001) 1.47
In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci (1996) 1.46
Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol (2011) 1.46
Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. Br J Pharmacol (1987) 1.45
Autoantibodies in systemic vasculitis. Aust N Z J Med (1991) 1.44
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem (2000) 1.44
A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem (1999) 1.43
Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol (1991) 1.42
Practice-induced changes of brain function during visual attention: a parametric fMRI study at 4 Tesla. Neuroimage (2004) 1.42
A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol (1987) 1.42
Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett (1986) 1.42